Detalles de la búsqueda
1.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
N Engl J Med
; 390(10): 875-888, 2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38446675
2.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38634928
3.
The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition.
Eur J Nucl Med Mol Imaging
; 2024 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38884773
4.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Future Oncol
; : 1-19, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38861289
5.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Future Oncol
; : 1-19, 2024 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38682738
6.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676282
7.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
J Transl Med
; 21(1): 75, 2023 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36737752
8.
Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study.
J Transl Med
; 21(1): 3, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36600265
9.
Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study.
Eur Radiol
; 33(5): 3343-3353, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36892650
10.
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network.
Support Care Cancer
; 31(7): 425, 2023 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358628
11.
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer.
J Oncol Pharm Pract
; 29(7): 1748-1753, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37282554
12.
Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy.
Int J Technol Assess Health Care
; 39(1): e2, 2023 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36606465
13.
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network.
Oncologist
; 27(12): e949-e956, 2022 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920559
14.
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
BMC Med
; 20(1): 48, 2022 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35101049
15.
Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study.
J Transl Med
; 20(1): 230, 2022 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35568887
16.
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
J Transl Med
; 20(1): 435, 2022 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36180954
17.
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Eur J Nucl Med Mol Imaging
; 49(3): 1063-1074, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34486070
18.
Rare anti-VEGFR therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient.
Anticancer Drugs
; 33(1): e724-e729, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34261919
19.
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients.
Int J Mol Sci
; 23(9)2022 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35563100
20.
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Oncology
; 99(12): 747-755, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34583356